TSXV:NRTH

Stock Analysis Report

Executive Summary

48North Cannabis Corp. operates as a cannabis company in the female health and wellness market in Canada.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Risks

  • 48North Cannabis is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has 48North Cannabis's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.8%

NRTH

-5.9%

CA Pharmaceuticals

1.3%

CA Market


1 Year Return

9.7%

NRTH

-46.7%

CA Pharmaceuticals

-0.1%

CA Market

NRTH outperformed the Pharmaceuticals industry which returned -46.7% over the past year.

NRTH outperformed the Market in Canada which returned -0.1% over the past year.


Share holder returns

NRTHIndustryMarket
7 Day-4.8%-5.9%1.3%
30 Day1.3%-1.4%4.7%
90 Day-2.5%-24.2%1.6%
1 Year9.7%9.7%-46.7%-46.7%3.4%-0.1%
3 Yearn/a219.2%217.3%19.1%8.4%
5 Yearn/a286.4%286.4%23.2%5.7%

Price Volatility Vs. Market

How volatile is 48North Cannabis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 months ago | Simply Wall St

Are Insiders Buying 48North Cannabis Corp. (CVE:NRTH) Stock?

Valuation

Is 48North Cannabis undervalued based on future cash flows and its price relative to the stock market?

2.03x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for 48North Cannabis to establish if it is available at moderate discount.

Unable to calculate intrinsic value for 48North Cannabis to establish if it is available at substantial discount.


Price Based on Earnings

48North Cannabis is loss making, we can't compare its value to the CA Pharmaceuticals industry average.

48North Cannabis is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for 48North Cannabis, we can't assess if its growth is good value.


Price Based on Value of Assets

48North Cannabis is good value based on assets compared to the CA Pharmaceuticals industry average.


Next Steps

Future Growth

How is 48North Cannabis expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

81.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

48North Cannabis's revenue is expected to grow significantly at over 20% yearly.

48North Cannabis's earnings are expected to grow significantly at over 20% yearly.

48North Cannabis's revenue growth is expected to exceed the Canada market average.

48North Cannabis's earnings growth is expected to exceed the Canada market average.

48North Cannabis's earnings growth is expected to exceed the low risk savings rate of 1.9%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if 48North Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has 48North Cannabis performed over the past 5 years?

10.8%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

48North Cannabis does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare 48North Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare 48North Cannabis's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if 48North Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if 48North Cannabis has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if 48North Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is 48North Cannabis's financial position?


Financial Position Analysis

48North Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

48North Cannabis's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

48North Cannabis has no debt.

48North Cannabis currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

High level of physical assets or inventory.

48North Cannabis has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

48North Cannabis has sufficient cash runway for 2.9 years based on current free cash flow.

Unable to confirm if 48North Cannabis has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is 48North Cannabis's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate 48North Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate 48North Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as 48North Cannabis has not reported any payouts.

Unable to verify if 48North Cannabis's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as 48North Cannabis has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of 48North Cannabis's salary, the management and board of directors tenure and is there insider trading?

1.4yrs

Average management tenure


CEO

Alison Gordon 0

0yrs

Tenure

CA$777,505

Compensation

Ms. Alison Gordon is Chief Executive Officer at 48North Cannabis Corp. since September 10, 2019. Ms. Gordon served as Co- Chief Executive Officer since November 30, 2018 until September 10, 2019 and serves ...


CEO Compensation Analysis

Alison's remuneration is higher than average for companies of similar size in Canada.

Alison's compensation has increased whilst company is loss making.


Management Age and Tenure

1.4yrs

Average Tenure

The average tenure for the 48North Cannabis management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

65yo

Average Age

The average tenure for the 48North Cannabis board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by 48North Cannabis individual insiders in the past 3 months.


Recent Insider Transactions

BuyCA$80,58517 Sep 19
Paul Caland
EntityIndividual
Shares100,000
Max PriceCA$0.81
BuyCA$119,88930 Aug 19
Paul Caland
EntityIndividual
Shares150,500
Max PriceCA$0.81
BuyCA$41,00027 Aug 19
Paul Caland
EntityIndividual
Shares50,000
Max PriceCA$0.82
BuyCA$90,00012 Aug 19
Paul Caland
EntityIndividual
Shares100,000
Max PriceCA$0.90
BuyCA$16,00025 Jul 19
Paul Caland
EntityIndividual
Shares20,000
Max PriceCA$0.80
BuyCA$81,00022 Jul 19
Paul Caland
EntityIndividual
Shares100,000
Max PriceCA$0.81
BuyCA$82,81219 Jul 19
Paul Caland
EntityIndividual
Shares101,000
Max PriceCA$0.82
BuyCA$82,00011 Jul 19
Paul Caland
EntityIndividual
Shares100,000
Max PriceCA$0.82
BuyCA$81,00010 Jul 19
Paul Caland
EntityIndividual
Shares100,000
Max PriceCA$0.81
BuyCA$2,87009 Jul 19
Paul Caland
EntityIndividual
Shares3,500
Max PriceCA$0.82
BuyCA$47,79003 Jul 19
Paul Caland
EntityIndividual
Shares59,000
Max PriceCA$0.81
BuyCA$162,00002 Jul 19
Paul Caland
EntityIndividual
Shares200,000
Max PriceCA$0.81
SellCA$909,93222 May 19
Groupe Lune Rouge Inc.
EntityCompany
Shares865,700
Max PriceCA$1.19
BuyCA$19,80017 Apr 19
Alison Gordon
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares20,000
Max PriceCA$0.99
BuyCA$19,95506 Dec 18
Martin Cauchon
EntityIndividual
Role
Chairman of the Board
Chairman
Shares30,700
Max PriceCA$0.65

Ownership Breakdown


Management Team

  • David Hackett (54yo)

    Chief Financial Officer

    • Tenure: 1.4yrs
    • Compensation: CA$165.51k
  • Alison Gordon

    CEO & Director

    • Tenure: 0yrs
    • Compensation: CA$777.51k
  • Kevin Helfand

    Chief Operating Officer

    • Tenure: 2yrs
    • Compensation: CA$474.43k
  • Kirsten Gauthier

    Chief Marketing Officer

    • Tenure: 0yrs
  • Charles Vennat

    Chief Corporate Officer

    • Tenure: 0.08yrs

Board Members

  • Martin Cauchon

    Chairman

    • Tenure: 0yrs
  • Bill Assini (65yo)

    Director

    • Tenure: 1.3yrs
  • Jim Gervais (81yo)

    Director

    • Tenure: 1.3yrs
  • Anne Darche (63yo)

    Director

    • Tenure: 1.3yrs
  • Alison Gordon

    CEO & Director

    • Tenure: 0yrs
    • Compensation: CA$777.51k
  • Jeannette VanderMarel

    Director

    • Tenure: 0.8yrs
  • Alain Dubuc

    Director

    • Tenure: 1.3yrs

Company Information

48North Cannabis Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 48North Cannabis Corp.
  • Ticker: NRTH
  • Exchange: TSXV
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$134.880m
  • Shares outstanding: 170.73m
  • Website: https://www.48nrth.com

Location

  • 48North Cannabis Corp.
  • 243 Queen Street West
  • 2nd Floor
  • Toronto
  • Ontario
  • M5V 1Z4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NRTHTSXV (TSX Venture Exchange)YesCommon SharesCACADJun 2018
NCNN.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2018

Biography

48North Cannabis Corp. operates as a cannabis company in the female health and wellness market in Canada. The company, through its subsidiary, DelShen Therapeutics Corp., grows genetics and owns 800-acres  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:46
End of Day Share Price2019/09/20 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.